Charles River Laboratories Intl. (NYSE:CRL) had its target price increased by KeyCorp from $140.00 to $151.00 in a research note published on Monday. KeyCorp currently has an overweight rating on the medical research company’s stock. KeyCorp also issued estimates for Charles River Laboratories Intl.’s Q1 2019 earnings at $1.38 EPS and Q2 2019 earnings at $1.60 EPS.

CRL has been the topic of a number of other reports. ValuEngine cut Charles River Laboratories Intl. from a buy rating to a hold rating in a research note on Friday, January 4th. SunTrust Banks raised their target price on Charles River Laboratories Intl. to $151.00 and gave the company a buy rating in a research note on Thursday, February 14th. Deutsche Bank assumed coverage on Charles River Laboratories Intl. in a research note on Friday, December 14th. They issued a buy rating on the stock. Zacks Investment Research upgraded Charles River Laboratories Intl. from a sell rating to a hold rating and set a $156.00 target price on the stock in a research note on Thursday, February 14th. Finally, Barclays reiterated a hold rating and issued a $135.00 target price on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $141.71.

Shares of CRL opened at $140.99 on Monday. Charles River Laboratories Intl. has a 12-month low of $101.58 and a 12-month high of $146.31. The firm has a market cap of $6.78 billion, a P/E ratio of 23.38, a PEG ratio of 1.81 and a beta of 1.04. The company has a current ratio of 1.61, a quick ratio of 1.38 and a debt-to-equity ratio of 1.24.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 13th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.10. The firm had revenue of $605.53 million for the quarter, compared to analysts’ expectations of $589.86 million. Charles River Laboratories Intl. had a return on equity of 24.09% and a net margin of 9.99%. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period last year, the business posted $1.40 earnings per share. As a group, analysts predict that Charles River Laboratories Intl. will post 6.48 EPS for the current fiscal year.

In other news, Chairman James C. Foster sold 25,000 shares of the firm’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $115.00, for a total transaction of $2,875,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 5,522 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $137.61, for a total value of $759,882.42. Following the transaction, the executive vice president now directly owns 16,325 shares in the company, valued at $2,246,483.25. The disclosure for this sale can be found here. Insiders have sold 57,428 shares of company stock worth $7,472,693 over the last three months. Corporate insiders own 2.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of CRL. Fort L.P. acquired a new position in Charles River Laboratories Intl. during the fourth quarter worth about $27,000. Riverview Trust Co acquired a new position in Charles River Laboratories Intl. during the fourth quarter worth about $30,000. Kwmg LLC grew its holdings in Charles River Laboratories Intl. by 32.4% during the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after acquiring an additional 105 shares during the period. Captrust Financial Advisors grew its holdings in Charles River Laboratories Intl. by 101.3% during the fourth quarter. Captrust Financial Advisors now owns 612 shares of the medical research company’s stock worth $69,000 after acquiring an additional 308 shares during the period. Finally, Csenge Advisory Group acquired a new position in Charles River Laboratories Intl. during the third quarter worth about $91,000. 94.03% of the stock is currently owned by institutional investors.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Book Value Per Share – BVPS

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.